<DOC>
	<DOC>NCT00669409</DOC>
	<brief_summary>To evaluate the safety and tolerability of single IV doses of PF-04383119 in Japanese patients with moderate to severe pain from OA of the knee (Part I). To evaluate the preliminary analgesic efficacy of PF-04383119 in Japanese patients with moderate to severe pain from OA of the knee in comparison with placebo (Part I and Part II).</brief_summary>
	<brief_title>A Phase 1/2A, Single Dose Study Of PF-04383119 In Japanese Patients With Moderate To Severe Pain From Osteoarthritis Of The Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>Japanese Male or female, Age 3565 (Part 1), Age 3575 (Part 2) Diagnosis of osteoarthritis (OA) of the knee based on American College of Rheumatology criteria Knee pain, and radiographic evidence of knee OA (KellgrenLawrence xray grade â‰¥2) obtained within 1 year of enrollment At least one of the following: age &gt;50, morning stiffness &lt;30 minutes in duration, crepitus, and OA of the knee must involve the index tibiofemoral joint and must have present for at least 6 months Patients who meet at least one of the following: unwilling to take nonopiate pain medications, or for whom nonopiate pain medications have failed, or are candidates for or seeking invasive interventions such as intraarticular injections, knee arthroplasty, or total knee surgery Pain levels as required by the protocol at Screening and Baseline Diagnosis or history of RA, any inflammatory arthritis, gout, Paget's disease or any other disease that in the Investigator's opinion would interfere with the assessment of pain and other symptoms of OA Patients with regional pain syndromes suggestive of fibromyalgia or regional pain caused by lumbar or cervical compressions with radiculopathy or at risk of developing radiculopathy. Diagnosis or history of fibromyalgia Planned surgical procedure during the duration of the study</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>monoclonal antibody</keyword>
</DOC>